FAST kinase domains 5Genealiases: MC4DN24 · dJ1187M17.5
Q-omics provides the consensus-scored FASTKD5 profile across patient tissues and cancer cell-line models. FASTKD5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FASTKD5 is differentially expressed in 14, with the highest sampling consensus in STAD. Additionally, FASTKD5 protein abundance shows 23,081 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, STAD, and LSCC as cancer lineages where FASTKD5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FASTKD5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FASTKD5 survival associations across molecular data types. FASTKD5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FASTKD5 RNA expression–survival associations across cancer types. High FASTKD5 expression shows unfavorable associations in UVM, LIHC, MESO, LGG and CHOL, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FASTKD5 RNA expression.
This table summarizes FASTKD5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FASTKD5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FASTKD5 shows lower tumor expression in THCA and KIRC and higher tumor expression in STAD, LIHC, BRCA and HNSC. The STAD box plot shows higher FASTKD5 RNA expression in tumor versus normal tissue (log2 FC = +1.072, t-test p < 0.001).
This table shows molecular features associated with FASTKD5 in patient tissues and cancer cell lines. In patient samples, FASTKD5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FASTKD5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
